VII Programma Quadro UE
European Commission: EU Research Funding 2017-2013
Unbiased biomarkers for the prediction of respiratory disease outcomes - U-BIOPRED
Innovative Medicines Initiative (Joint iTechnology (public-private partnership) - DG Research and European Federation of Pharmaceutical Industries and Associations (EFPIA)
Total cost: € 26.925.702.00
The U-BIOPRED project aims to speed up the development of better treatments for patients with severe asthma. Several knowledge gaps today make it hard to predict in the early stages of drug development how well a new experimental medicine will work in patients. One of the major difficulties is the finding that there are many different forms of severe asthma, caused by different mechanisms of disease. Patients with different types of asthma may react differently to new or existing treatments.
Project Coordinator and Managing entity: Peter Sterk Dept. Respiratory Medicine, Academic Medical Centre Amsterdam, The Netherlands
Participant (Universities, Research Organisations, Public Bodies): prof. Riccardo POLOSA
European Multicentre Tics in Children Studies: translating pre-clinical results into terapie - EMTICS
Grant agreement n° 278367. EC contribution: € 6,000,000.00
EMTICS will undertake pre-clinical and cohort studies that address susceptibility factors for paediatric and adolescent tic disorders, with a particular focus on comorbid obsessive-compulsive symptomatology, from clinical, epidemiological, genetic, microbiological and immunological angles. EMTICS aims to elucidate the complex aetiology of the onset and clinical course of chronic tic disorders and associated obsessive-compulsive symptoms, through disentangling the interplay between environmental factors and genetic background; translate research findings into clinical applications by developing disease prediction models and investigation of a treatment strategy; and will establish a Pan-European infrastructure for the study of tic disorders.
Project Coordinator: Dr. Pieter Hoekstra (University Medical Center, Dept. of Child and Adolescent Psychiatry, Groningen (The Netherlands)
WP10 (Training and Dissemination): Project leader prof.ssa Renata RIZZO
European IPF Network: Natural course, Pathomechanisms and Novel Treatment Options in Idiopathic Pulmonary Fibrosis – eurIPFnet
Project reference: 202224.
In the eurIPFnet consortium, leading European basic and clinical scientists in the field of interstitial lung diseases associate to jointly decipher the natural course and molecular pathomechanisms of Idiopathic Pulmonary Fibrosis (IPF) and to develop new therapeutic strategies for patients with IPF. Our translational research programme includes implementation of a European IPF registry (eurIPFreg), in which data with regard to natural course, familiar background and susceptibility factors of IPF will be collected, and of a European IPF biobank (eurIPFbank) of blood, bronchoalveolar lavage fluid, cells and tissue specimen of IPF.
Project Coordinator: Justus-Liebig-Universitaet Giessen, Germany
Participant (Universities, Research Organisations, Public Bodies): prof. Carlo VANCHERI
Cfr: European IPF Registry (eurIPFreg)